

## **Artificial Intelligence and Smart Wearables to Help Cancer Survivors**

### **MCS Part of Prestigious European Cancer Research & Innovation Effort**

**Brussels; Jan. 1, 2020. MCS Data Labs GmbH, based in Berlin (Germany) announced its participation in a European-wide cancer research and innovation project, financed by the European Commission. The project aims to support post-treatment cancer patients by utilizing Artificial Intelligence (AI) and smart wearables.**

The burden of cancer is rising globally and is estimated to have reached 18.1 million new cases. Despite the rising cancer incidences, improvements in early detection and therapeutic treatment have improved cancer survival. As a consequence, the number of cancer survivors is increasing globally, creating the need to improve not only treatment but also wellness and follow-up care.

ONCORELIEF is a 36-month action, starting on January 1, 2020, that is built around the post-treatment recovery of cancer patients. Particular attention is given to the personal situation a cancer patient goes through following treatment.

ONCORELIEF will be built upon the latest advancements in occupational psychology, health science and technology. It is developing a user-centered AI system to create an intuitive smart digital assistant called Guardian Angel. Not only will it provide personalized support in post-treatment activities and tasks, it will also suggest actions regarding the patients' overall health-status, improved well-being and active healthcare.

MCS' technology will play a central role within the project. The company will utilize its AI, hardware and software knowhow to develop an ecosystem as part of the overall ONCORELIEF effort. A wearable device will collect vital and other data from patients in a secure and safe way to support decision making both by caretakers and patients. Sensors, data thresholds and alarm triggers will be determined by patient and caretaker needs that the research consortium identifies as being most relevant. MCS will be part of a pilot study within the research project, dedicated to colorectal cancer.

‘It is the first time that our technology supports in the meaningful and important effort to improve the lives of post-treatment cancer patients’, says Suheib Mousa, CEO of MCS. ‘We are glad to make an impact in an area the European Commissions considers as strategically important for achieving the healthcare goals of this decade. Even we are small as a company, our contribution to the project is considered crucial.’

The consortium consists of prestigious universities, research organizations and companies across Europe and is funded by the European Commission with a budget of slightly below EUR 10 million (grant agreement ID: 875392).

For further information contact:

**MCS Data Labs GmbH**  
**Bismarckstr. 10-12**  
**10625 Berlin**

**phone: +49 30 59 00 83 280**  
**fax: +49 30 59 00 83 208**  
[info@mcs-datalabs.com](mailto:info@mcs-datalabs.com)  
[www.mcs-datalabs.com](http://www.mcs-datalabs.com)

#### About MCS Data Labs

**MCS Data Labs, a privately owned technology firm in Berlin (Germany), is predominantly engaged in hardware and software for digital health and public safety. Main competencies of the company include wearable technologies, Artificial intelligence, IoT and machine learning. The SME is consortium member in several large European research and innovation projects that focus on cancer, motion detection, diabetes and pandemic prevention. Flagship project is its proprietary SmarKo<sup>®</sup> Health ecosystem for remote patient monitoring. CEO is Suheib Mousa.**



This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement number 875392.